We are live on
!
Find out more
EC
EcoR1 Capital Portfolio holdings
AUM
$2.06B
Turnover
46.34%
1-Year Est. Return
215.32%
This Fund
S&P 500
This Quarter
Est. Return
-12.61%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$2.9B
AUM Growth
-$300M
(-9.4%)
Cap. Flow
+$207M
Cap. Flow
% of AUM
7.15%
Top 10 Holdings %
Top 10 Hldgs %
60.65%
Holding
101
New
14
Increased
15
Reduced
4
Closed
21
Avg Time Held Equity + Options
1
year
Top 10 Avg Time Held Equity + Options
1.3
years
Top 20 Avg Time Held Equity + Options
1.3
years
Avg Time Held Equity only
1
year
Top 10 Avg Time Held Equity only
1.3
years
Top 20 Avg Time Held Equity only
1.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$145M |
| 2 |
Arvinas
ARVN
|
+$81.3M |
| 3 |
Sarepta Therapeutics
SRPT
|
+$58.7M |
| 4 |
Revolution Medicines
RVMD
|
+$58.5M |
| 5 |
Allogene Therapeutics
ALLO
|
+$39.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Arcus Biosciences
RCUS
|
+$103M |
| 2 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$41.2M |
| 3 |
Vaxcyte
PCVX
|
+$31.5M |
| 4 |
Bicycle Therapeutics
BCYC
|
+$24M |
| 5 |
Exelixis
EXEL
|
+$19.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.48% |
| 2 | Miscellaneous | 0.84% |
| 3 | Financials | 0.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
DELISTED
Crinetics Pharmaceuticals
CRNX
| $24.8M | 0.86% |
1,330,263
+540,054
| +68% | +$10.8M |
2021 Q4
2 quarters
|
|
27
Geron
GERN
$790M
| $22M | 0.76% |
14,168,988
-116,726
| -0.8% | -$165K |
2022 Q1
1 quarter
|
|
28
Arcutis Biotherapeutics
ARQT
$3.66B
| $19.1M | 0.66% |
895,503
| – | – |
2022 Q1
1 quarter
|
|
29
Edgewise Therapeutics
EWTX
$4.15B
| $18.8M | 0.65% |
2,359,808
| – | – |
2021 Q1
5 quarters
|
|
30
Janux Therapeutics
JANX
$1.06B
| $17.4M | 0.6% |
1,421,319
| – | – |
2021 Q2
4 quarters
|
|
31
DELISTED
Ventyx Biosciences
VTYX
| $15.9M | 0.55% |
1,300,000
| – | – |
2021 Q4
2 quarters
|
|
|
32
CALL
Exelixis
EXEL
$15.6B
| $15.8M | 0.55% |
+760,000
| New | +$15.7M |
2022 Q2
0 quarters
|
|
33
Oric Pharmaceuticals
ORIC
$1.32B
| $15.3M | 0.53% |
3,418,068
| – | – |
2020 Q2
8 quarters
|
|
34
Cullinan Oncology
CGEM
$901M
| $15M | 0.52% |
+1,169,889
| New | +$13.3M |
2022 Q2
0 quarters
|
|
35
Incyte
INCY
$23B
| $13.9M | 0.48% |
+182,783
| New | +$13.9M |
2022 Q2
0 quarters
|
|
36
Ovid Therapeutics
OVID
$441M
| $13.2M | 0.45% |
6,117,400
| – | – |
2021 Q1
5 quarters
|
|
|
KDNY
37
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $12.1M | 0.42% |
690,000
| – | – |
2022 Q1
1 quarter
|
|
|
GRCL
38
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
| $10.6M | 0.36% |
1,921,310
+361,600
| +23% | +$1.12M |
2022 Q1
1 quarter
|
|
39
Tango Therapeutics
TNGX
$3.83B
| $10.4M | 0.36% |
2,302,065
+1,540,094
| +202% | +$9.32M |
2020 Q3
7 quarters
|
|
|
AKUS
40
DELISTED
Akouos Inc
AKUS
| $9.27M | 0.32% |
1,975,984
| – | – |
2020 Q2
8 quarters
|
|
41
DELISTED
HOOKIPA Pharma
HOOK
| $8.15M | 0.28% |
500,000
| – | – |
2022 Q1
1 quarter
|
|
42
Precision BioSciences
DTIL
$170M
| $8.06M | 0.28% |
+167,866
| New | +$9.85M |
2022 Q2
0 quarters
|
|
|
SURF
43
DELISTED
Surface Oncology, Inc. Common Stock
SURF
| $7.63M | 0.26% |
4,653,000
| – | – |
2022 Q1
1 quarter
|
|
|
NGM
44
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $6.94M | 0.24% |
541,108
| – | – |
2022 Q1
1 quarter
|
|
|
FLAC
45
DELISTED
Frazier Lifesciences Acquisition Corporation Class A Ordinary Shares
FLAC
| $5.8M | 0.2% |
587,615
| – | – |
2021 Q2
4 quarters
|
|
46
DELISTED
iTeos Therapeutics
ITOS
| $5.77M | 0.2% |
279,999
+207,178
| +285% | +$4.92M |
2020 Q3
7 quarters
|
|
|
JYAC
47
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
| $4.94M | 0.17% |
500,000
| – | – |
2020 Q4
6 quarters
|
|
48
Aligos Therapeutics
ALGS
$33.7M
| $4.78M | 0.16% |
157,934
| – | – |
2021 Q4
2 quarters
|
|
49
Cartesian Therapeutics
RNAC
$199M
| $4.58M | 0.16% |
+116,667
| New | +$3.46M |
2022 Q2
0 quarters
|
|
|
AVEO
50
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
| $4.25M | 0.15% |
+647,489
| New | +$3.14M |
2022 Q2
0 quarters
|
|
Similar funds
RHJA
ST
ABTD
CFA
DWT
RMC
SIC
FWTB
EcoR1 Capital's Q2 2022 Portfolio in Review
As of Q2 2022, EcoR1 Capital held 101 positions worth $2.9B, down 9.4% from $3.2B the previous quarter. Its ten largest holdings account for 61% of the portfolio.
EcoR1 Capital deployed $207M of net new capital in Q2 2022, opening 14 new positions and adding to 15 existing holdings. Its largest new stake was Seagen Inc. Common Stock: 1,008,628 shares worth $178M.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Miscellaneous and Financials.
On the sell side, the largest reduction was Alector, an estimated $16.8M trimmed.
- EcoR1 Capital's largest Q2 2022 buy was Seagen Inc. Common Stock: 1,008,628 shares worth $178M.
- EcoR1 Capital added most to Arvinas in Q2 2022, an estimated $81.3M increase.
- EcoR1 Capital's biggest Q2 2022 reduction was Alector, cutting an estimated $16.8M.
- EcoR1 Capital fully exited Arcus Biosciences in Q2 2022, selling an estimated $103M.
- EcoR1 Capital's ten largest holdings make up 61% of its $2.9B portfolio in Q2 2022.
- EcoR1 Capital opened 14 new positions and closed 21 in Q2 2022.
- EcoR1 Capital's portfolio value fell 9.4% quarter-over-quarter to $2.9B.
Based on EcoR1 Capital's 13F filing for Q2 2022, filed 15 Aug 2022.